Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897778 · ClinicalTrials.gov registry record · Phase 1
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
A Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02897778: Completed Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, sponsored by Syndax Pharmaceuticals.
NCT02897778 is a Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 30 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02897778, a Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and pharmacodynamic parameters.
Primary Outcome
Heart rate measured in beats per minute (bpm).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Entinostat
Study Locations (1)
Texas
- The START Center for Cancer Care - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-08-24 |
| Est. Completion | 2017-03-13 |
| Phase | Phase 1 |
What the finished NCT02897778 record still lists
NCT02897778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower).
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02897778 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02897778 about?
NCT02897778 is a clinical study titled "Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors". The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and pharmacodynamic parameters.
What is the current status of trial NCT02897778?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-08-24. Estimated completion is 2017-03-13.
What conditions does trial NCT02897778 study?
This clinical trial studies the following conditions: Neoplasms, Carcinoma, Non-Small Cell Lung, Lung Neoplasms, Neoplasms by Histologic Type, Thoracic Neoplasms.
What interventions are being tested in trial NCT02897778?
The interventions under investigation include: Placebo (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT02897778?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02897778 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02897778's enrollment target sits among peer trials
30 134th of 158 higher than 21 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI